Investigating how certain proteins interact with HIV-1 during early infection
Official title: +TIPs as novel host capsid-binding co-factors in early HIV-1 infection
Funded at Northwestern University at Chicago · NIH-11017810 · Data updated 2026-11-12
This study is looking at how certain proteins in our bodies interact with the HIV virus in its early stages, which could help scientists find new ways to treat HIV and improve care for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Northwestern University at Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project start | March 9, 2023 |
| Project end | February 29, 2028 |
| Funding year | 2025 |
| Award (this year) | $734,072 |
| NIH project number | 5R01AI172818-03 |
| Project ID | NIH-11017810 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at risk of HIV infection or those in the early stages of HIV infection.
✕Less likely to help
Patients with chronic HIV infection or those who are already on antiretroviral therapy may not benefit directly from this research.
What this research studies
This research explores the early stages of HIV-1 infection, focusing on how specific host proteins interact with the virus's capsid, which is crucial for its stability and transport within the host cell. The study aims to identify and characterize these interactions using advanced techniques like cryo-electron microscopy. By understanding these mechanisms, researchers hope to uncover new targets for therapeutic intervention that could disrupt the viral life cycle. Patients may benefit from insights that could lead to innovative treatments for HIV.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies for preventing or treating HIV infection.
How similar studies have gone: Previous research has shown promise in targeting host-virus interactions, suggesting that this approach could yield significant advancements in HIV treatment.
Where this research is happening
-
Northwestern University at Chicago
Chicago, United States Active
Researchers
- Principal investigator: Naghavi, Mojgan Hosseini — Northwestern University at Chicago
- Study coordinator: Naghavi, Mojgan Hosseini
Related research
Other NIH-funded projects on the same topics.
-
BEAT-HIV: a collaborative effort to cure HIV with immunotherapy
A multi-institution study is testing a combination immunotherapy approach to achieve long-term HIV remission or cure for people on ART.
-
Phosphatidylserine-targeting antibodies and T cell function in HIV-1 infection
This NIH grant will explore how antibodies that target phosphatidylserine affect immune cells in people living with HIV on ART.
-
Ribosomal frameshifting in HIV-1 infection and its effects on inflammation and brain health
A study at the University of Rochester will explore how HIV-1 may change human cell machinery to boost its own replication and cause inflammation and brain-related problems.
-
Targeting NLRP3 inflammasome to protect HIV patients from stroke
A small NIH grant will explore whether HIV infection makes stroke worse and whether blocking a brain inflammation pathway (NLRP3) could protect brain tissue.
-
Reprogramming tissue immune cells (macrophages) to target hidden HIV
Trying small drug molecules to reprogram tissue immune cells so infected cells die and hidden HIV is reduced in people living with HIV.
-
EHD4 protein and HIV-1 infection: a new potential antiviral target
A study to understand how the human protein EHD4 affects HIV-1 infection and whether it could be targeted to develop better antiviral therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.